- timsTOF Ultra 2 enables significant further improvements in
deep, high-fidelity 4D-Proteomics™ of mammalian cells, cancer cell
lines, or tissue biopsies
- With sensitivity to measure >1000 proteins on just 25 pg,
the timsTOF Ultra 2 opens new cell and disease biology research
windows into PBMCs, small immune cells, bacterial cells, or
subcellular organelle proteomics
- timsTOF Ultra 2 enables identification and quantitation of
~50% more protein groups and ~100% more peptides at 25 pg of digest
sample with 1% FDR
- timsTOF Ultra 2 typically yields ~40% more peptides and ~20%
more proteins for many other 4D-Proteomics applications with
low-medium sample amounts
- Improved ion-charge control (ICC 2.0) method makes timsTOF
Ultra 2 suitable for a very broad range of sample loading, from low
picograms to micrograms
- New OmniScape™ top-down proteoform software
for automated, near-complete protein sequence coverage from
MALDI-ISD and LC-TIMS-MS/MS data
- Biognosys launches Spectronaut® 19 (SN19) with optimized AI
for further increased depth of protein quantitation and greater
peptide sequence coverage
- SN19 now specifically trained on timsTOF MS/MS for
significant 4D-Proteomics performance improvements; SN19 now fully
integrated into timsTOF Ultra 2
- PreOmics launches reproducible and affordable deep plasma
4D-Proteomics ENRICHplus kit for 7-fold plasma depth improvement on
robust timsTOF HT
- Novel capabilities for 4D-glycoprotein analysis:
glyco-PASEF® and GlycoScape™
- Bruker announces customer shipment of more than 1,000
timsTOF systems
- Bruker launches 3 mass spectrometers at ASMS 2024 for
4D-Proteomics, mass-spec multiomics tissue imaging, and for
highest-confidence applied analysis
At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR)
launches the new top-of-the-line timsTOF Ultra 2 system with
significantly further enhanced sensitivity for deep profiling of
small cells, subcellular organelles, as well as increased sample
loading flexibility. Together with new Spectronaut 19
software and the novel PreOmics ENRICHplus kit, Bruker is
setting new 4D-Proteomics standards from highest sensitivity to
large-scale, deep plasma proteomics. Bruker is also introducing
OmniScape software for top-down sequence confirmation and de
novo sequencing for intact, undigested proteoforms, dissociated in
the mass spectrometer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240603348539/en/
The new timsTOF Ultra 2 delivers ultimate
sensitivity (Photo: Business Wire)
Bruker Advances Ultimate Sensitivity with new timsTOF Ultra
2
The new timsTOF Ultra 2 delivers ultimate sensitivity of up to
50% more protein groups and up to 100% more peptides on just 25 pg
of protein digest, i.e. only 1/10th the protein mass of a HeLa
cell. This makes timsTOF Ultra 2 the best choice to investigate
immune homeostasis surveying low abundance proteins from small
peripheral blood mononuclear cells (PBMCs), or from bacterial cells
comprising the microbiome, or for immunopeptidomics to discover
cancer neoantigens from fine needle biopsies.
New ion charge control (ICC2.0) software provides sample loading
flexibility from low picogram amounts to about a microgram of
protein digest.
Bruker ProteoScape™ software now integrates Spectronaut 19
(SN19) software from Biognosys, the gold-standard for
data-independent analysis (DIA). The new SN19 offers significantly
improved search engine AI, advanced quantification, and
allows precise predictions of timsTOF’s unique collision cross
sections (DeepCCS), retention time (DeepiRT) and fragment ion
intensity (DeepFrag), resulting in a 13% average increase in
protein group identifications and improvements in quantification
precision. See Biognosys Press Release
Bruker once again intends to offer field upgrades to the timsTOF
Ultra 2 for timsTOF Ultra/SCP customers.
PreOmics launches Reproducible, Affordable ENRICHplus Deep
Plasma 4D-Proteomics Solution, Leveraging the Proven Robustness of
the timsTOF HT
The new single particle PreOmics ENRICHplus kit and the
timsTOF HT now deliver up to 7-fold improvement in protein
identification and quantification versus neat plasma. The increased
depth of coverage, together with field-proven throughput and
robustness of the timsTOF HT enables deep plasma proteomics at
scale. See PreOmics Press Release
Dr. Roman Fischer, Associate Professor and Head of
Discovery, Proteomics Facility, University of Oxford, UK, stated:
"timsTOF technology, together with ENRICHplus, is changing the way
we do plasma proteomics. On our timsTOF Pro we achieve on average
3800 protein identifications per sample with a throughput of 60
samples per day, while only using 20 µl of plasma. We never before
achieved such depth with a single run of plasma, now enabling us to
detect tissue leakage proteins and other low abundant potential
biomarkers for cancer and neurodegenerative diseases. Together with
the robust timsTOF system, ENRICHplus is game-changing for deep,
affordable plasma proteomics at scale."
Bruker Launches OmniScape Top-Down Software for Analysis of
Intact Proteins
Bruker is introducing OmniScape, the first top-down
protein sequence software that covers protein de novo sequencing
and lead sequence identification through homology searches for
detailed proteoform analysis.
Dr. Boris Krichel, University of Wisconsin-Madison,
summarized: “I am excited about the de novo sequencing to discover
and annotate proteins in untargeted top-down proteomics. The most
impressive function of OmniScape is the automatic suggestion of
matching proteoforms based on multiple variable modifications.”
OmniScape supports different data types from LC-CCS-MS/MS,
enabling for example the analysis of multiply phosphorylated
proteins. Its ability to integrate different datasets yields very
high sequence coverages, providing reliable sequence calls and
PTMs. OmniScape can also process MALDI-ISD top-down spectra from
the timsTOF fleX and axial MALDI instruments including the new
neofleX, as well as data from non-Bruker instruments as a
one-for-all top-down protein sequencing and isoform determination
software solution.
Dr. Christian Isak Jørgensen, Senior Science Manager,
Novonesis, Denmark, added: “OmniScape addresses a real need in the
biotech industry producing recombinant proteins.”
Novel Acquisition and Computational Capabilities for
4D-Glycoproteomics
Bruker is introducing GlycoScape, the first real-time
glycoproteomic software. GlycoScape has been developed in
collaboration with the Radboud University Medical Center in the
public-private partnership project EnFORCE led by Dr. Hans Wessels
[1]. The software can identify glycopeptides on-the-fly as data are
acquired and without the need to rely on glycan libraries, not only
enabling identification of previously unreported glycans, but
significantly minimizing false negative results. The unbiased
read-out of glycoproteomic data by GlycoScape is critical for the
advancement of glycobiology in translational and clinical research
as these important research fields become accessible in the
post-genomic era.
Dr. Hans Wessels, Senior Researcher at Radboud University
in Nijmegen highlighted key advantages: “GlycoScape opens up the
analysis of glycoproteomic mass spectrometry data from the timsTOF
platform for on-the-fly processing without glycan database
restrictions.”
GlycoScape leverages the glyco-PASEF method for
ultra-sensitive and rapid glycoprotein data acquisition, using
stepped energy CID and oxonium-ion-gated polygon-filtering, that
was developed in collaboration with Prof. Albert Heck’s group at
Utrecht University.
Dr. Albert Heck, Professor of Chemistry and
Pharmaceutical Sciences at Utrecht University and Scientific
Director of the Netherlands Proteomics Center, noted: “I am pleased
with our pioneering work in leveraging the unique strengths of the
timsTOF platform for glycoproteomics, now translated to the
glyco-PASEF method for research in glycobiology.”
[1] The collaboration project is co-funded by PPP Allowance
awarded by Health~Holland, Top Sector Life Sciences & Health,
to stimulate public-private partnerships (Grant #LSHM21032).
About Bruker Corporation – the Emerging Leader of the
Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603348539/en/
Media Petra Scheffer Bruker Daltonics MarCom Manager T:
+49 (421) 2205-2843 E: Petra.Scheffer@bruker.com
Investor Relations Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
